All In Biotech

Free tool

FAERS Monitor: Ensacove

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 218171 or its brand name (Ensacove, Ensartinib Hydrochloride). Reports on generic versions are filed under their own applications.

Reports

45

Serious

34

76% of reports

Hospitalization

16

Death reported

5

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • rash9
  • pruritus7
  • constipation6
  • drug ineffective5
  • fatigue5
  • death4
  • disease progression4
  • oedema4
  • adverse event3
  • product use issue3
  • rash pruritic3
  • alanine aminotransferase increased2
  • aspartate aminotransferase increased2
  • atrial fibrillation2
  • confusional state2

Reports by year received

View as table
YearReports
20212
20224
20232
20246
20253
202628

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,054,114 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
oedemaSignal434.513.599
rash pruriticSignal325.98.749
aspartate aminotransferase increased217.64.517
disease progressionSignal415.86.242
alanine aminotransferase increased215.23.914
adverse eventSignal315.25.127
constipationSignal612.96.155
rashSignal99.75.463
atrial fibrillation29.62.58
pruritusSignal78.54.340
product use issueSignal37.52.511
confusional state25.81.54
fatigueSignal53.01.35
death42.20.92
drug ineffective51.80.81

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.